Table 3.
Hazard ratios (HR) for breast cancer-specific mortality from competing risks analysis.
| Type of Loco-Regional Treatment | Crude HR (95% CI) | Adjusted HR (95% CI) 1 | Adjusted HR (95% CI) 2 | Adjusted HR (95% CI) 3 |
|---|---|---|---|---|
| BCS + RT 4 | 1.00 | 1.00 | 1.00 | 1.00 |
| BCS 5 | 1.16 (0.75–1.78) | 1.13 (0.73–1.76) | 1.21 (0.77–1.88) | 1.11 (0.71–1.75) |
| MTX 6 | 1.73 (1.35–2.22) | 1.78 (1.37–2.30) | 1.45 (1.10–1.90) | 1.38 1.05–1.82) |
| MTX + RT 7 | 2.87 (1.93–4.27) | 2.73 (1.82–4.09) | 1.02 (0.65–1.60) | 1.05 (0.66–1.67) |
1 Adjusted for demographic factors: age, ethnicity, NZ deprivation, urban status, region, public/private; 2 Adjusted as above and for clinic-pathological factors: screen-detected/symptomatic, grade, hormone receptor status, histology, tumour size, lymph node status, lympho-vascular invasion (LVI); 3 Adjusted as above and for systemic treatment factors: chemo and hormonal therapies; 4 Breast Conserving Surgery plus Radiotherapy (BCS + RT); 5 Breast Conserving Surgery (BCS); 6 Mastectomy (MTX); 7 Mastectomy plus Radiotherapy (MTX + RT).